For those yearning for the day when biosimilars save the U.S. health care system huge amounts of money, consider a recent episode in Denmark.

In October 2018, the patent expired on Humira, a big-selling biologic drug that is used to treat rheumatoid arthritis, Crohn’s disease, and other ailments. The Danish government moved quickly and began accepting bids from companies that make biosimilar versions, which are nearly identical variants that are expected to yield the same health outcomes, but cost less than pricey brand-name biologics.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • As a Chrohn’s patient and retired healthcare professional, I’d like to see reports from Europe on the ongoing efficacy and safety of the Humira biosimilar.

    This is no defense of AbbVie although I am grateful for Humira’s beneficial effects (on me.) Indeed, without the copay assistance and a generous pharm benefit I’d not be about to comfortably afford the routine and customary charge for each shipment, if at all.

    Perhaps STAT or STAT+ can report further on the safety, in general, of biosimilars, especially those with significant side-effect considerations? While the risks are mathematically low, Humira, like any biologic, can cause serious and even life-threatening side effects. Hence, I’d like to know how high Europe sets the bar for trials safety.

    And, yeah, I know the Internet is out there but that’s why I pay for a STAT+ subscription – they do an excellent job of reporting.

    • Hi Robert,

      Thanks for the note.
      And you ask a good question. I will poke around and see what I can find.

      Appreciate that you took the time to write.

      Regards,
      ed at pharmalot

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy